Omega-3 phospholipid - Acasti Pharma

Drug Profile

Omega-3 phospholipid - Acasti Pharma

Alternative Names: CaPre; Long-chain-omega-3-phospholipid; NKPL-66

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acasti Pharma
  • Class Antihyperlipidaemics; Omega 3 fatty acids; Phospholipids
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypertriglyceridaemia

Most Recent Events

  • 20 Nov 2017 Acasti Pharma enters into a non-binding term sheet with an undisclosed company for commercialisation of omega-3 phospholipid for Hypertriglyceridaemia in Asia, including China
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Hypertriglyceridaemia(In volunteers) in USA (PO, Capsule)
  • 14 Aug 2017 Acasti Pharma plans to initiate phase III programme in Hypertriglyceridaemia in December 2017 (PO, Capsule) (NCT03361501)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top